<DOC>
	<DOC>NCT00592488</DOC>
	<brief_summary>This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.</brief_summary>
	<brief_title>Acetyl-L-Carnitine in the Treatment of Septic Shock</brief_title>
	<detailed_description>This is a cross-over study which infuses ALC for 12 out of 18 hours (and placebo the other 6). Patients must have vasopressor-dependent septic shock and be free from renal failure, hepatic failure, and seizures to be eligible.</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock, Septic</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>documented or presumed infection shock requiring vasopressors dialysis hepatic failure seizures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Septic shock</keyword>
	<keyword>Acetyl-L-carnitine</keyword>
</DOC>